AstraZeneca settles FCPA case with SEC for $5.5M
Biopharmaceutical-company AstraZeneca has reached a $5.5 million settlement with the SEC to settle claims that it violated the Foreign Corrupt Practices Act by making improper payments to state-controlled healthcare providers in China and Russia. Jaclyn Jaeger reports.
Related articles
-
PremiumEmerging Compliance Risks 2025: Laurie Waddy on Leadership, Anticorruption, and AI
Former Head of Compliance/Chief Compliance Officer Laurie Waddy believes compliance professionals are well-positioned to support artificial intelligence (AI) adoption in their organizations. Drawing on 25 years’ experience in legal and compliance roles across multiple industries, Waddy shares insights into top compliance trends confronting the profession, including the emerging compliance risks ...
-
News BriefDOJ declines to prosecute Liberty Mutual in $4.7M FCPA bribery case
Liberty Mutual agreed to give up $4.7 million in profit – the amount it earned from a bribery scheme uncovered by the government – as part of a settlement related to the Foreign Corrupt Practices Act, according to a letter from the U.S. Department of Justice.
-
ArticleDOJ, SEC end Investigations of GE HealthCare for possible FCPA violations in China
The Securities and Exchange Commission and Department of Justice ended a seven-year review of GE HealthCare Technologies’ China unit for possible violations of the Foreign Corrupt Practices Act.